Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

>. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

For further information, please visit www.delmarpharma.com
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 17, 2012 The " Anesthesia Drugs ... analyzes and studies the U.S. market for intravenous anesthesia drugs with ... buyers, export & import system for controlled substances in U.S. and U.S. ... in-depth TOC of   " Anesthesia Drugs ...
... clinical trial, a paralyzed woman was able to reach for and ... time in nearly 15 years by using her thoughts to ... the National Institutes of Health, is evaluating the safety and feasibility ... This is a type of brain-computer interface (BCI) intended to put ...
... 2012  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the Company,s common share repurchase program authorization by an ... of 2008, the Company has returned $236 million to ... and preferred shares, representing approximately 27% of its shares ...
Cached Biology Technology:Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5
(Date:4/24/2014)... puts out a welcome mat to bacteria seeking to invade, ... study published this week in the Proceedings of the ... battle between microbe and host that researchers can exploit to ... oft-studied plant Arabidopsis puts out a molecular signal ... a hostile army were unknowingly passing by a castle, and ...
(Date:4/23/2014)... chronic inflammatory disorders among people of lower socioeconomic status ... to the microbes that thrive in rural environments, according ... in the journal Clinical & Experimental Immunology , ... less access to green spaces may be more apt ... system dysfunction. , When our immune systems are working ...
(Date:4/23/2014)... new study from the Indiana University School of Public ... and heart disease by finding a strong association between ... coronary heart disease. , The study found that heme ... by 57 percent, while no association was found between ... sources, and coronary heart disease. , The study was ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Study: Iron consumption can increase risk for heart disease 2
... Researchers have identified genetic markers that may influence whether ... according to a national longitudinal study of thousands of young ... Developmental Psychology , a publication of the American Psychological Association. ... related in any way to academic achievement is a big ...
... laparoscopic surgery "minimally invasive" instruments enter the patient through ... work on different tasks, surgeons all see the same view. ... suited to the specific task? In a new paper, pediatric ... Brown University and Hasbro Children,s Hospital report that in a ...
... Cancer Center have uncovered a single molecule they say ... used to treat or prevent breast cancer in high-risk ... Cancer Research , the scientists say glucose-regulated protein 78 ... the agents tamoxifen and fulvestrant, turns off apoptosis, a ...
Cached Biology News:Genes may play role in educational achievement, study finds 2Individual perspectives improve laparoscopy 2Individual perspectives improve laparoscopy 3Single protein promotes resistance to widely used anti-estrogen drugs 2Single protein promotes resistance to widely used anti-estrogen drugs 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
E2F-5...
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Biology Products: